Recent advances in stroke therapy

Current Opinion in Neurology

Volumn 11, Issue 1, 1998, Pages 57-64

  Goldszmidt, Adrian ^a   Wityk, Robert J ^b,c  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CITICOLINE; CLOPIDOGREL; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LUBELUZOLE; NEUROPROTECTIVE AGENT; PLASMINOGEN ACTIVATOR; PRAVASTATIN; SIMVASTATIN; STREPTOKINASE; TIRILAZAD;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; STROKE;

ACUTE DISEASE; ANIMALS; CEREBROVASCULAR DISORDERS; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 0031983348     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199802000-00010     Document Type: Review

References (58)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Eng J Med 1995; 333:1581-1587.
2. Caplan LR, Mohr JP, Kistler JP, Koroshetz W. Thrombolysis - not a panacea for ischemic stroke. New Engl J Med 1997; 337:1309-1310.
3. Gratta J. t-PA-the best current opinion for most patients. New Engl J Med 1997; 337:1310-1313.
4. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997; 28:2119-2125.
5. Hacke W, Kaste M, Fieschi C, Toni D. Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
6. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. New Engl J Med 1996; 335:145-150.
7. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346:1509-1514.
8. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276:961-966.
9. Larrue V, von Kummer R, del Zoppo G. Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997; 28:957-960.
10. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28:2109-2118.
11. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice Advisory: thrombolytic therapy for acute ischemic stroke - summary statement. Neurology 1996; 47:835-839.
12. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute-ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Stroke 1996; 27:1711-1718. Detailed review of thrombolytic therapy and discussion of patient selection and care when using intravenous tPA for acute stroke.
13. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997; 350:607-614.
14. Dorman P, Sandercock P. TPA within 3 hours of acute ischaemic stroke? Lancet 1996; 348:1600-1601.
15. Indredavik B, Bakke F, Solberg R, Rokseth R, Haaheim L, Holme I. Benefit of a stroke unit: a randomized controlled trial. Stroke 1991; 22:1026-1031.
16. Langhorne P, Williams BO, Gilchrist W, Howie K. Do stroke units save lives? Lancet 1993; 342:395-398.
17. Jorgensen HS, Nakayama H, Raaschou HO, Larsen K, Hubbe P, Olsen TS. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study. Stroke 1995; 26:1178-1182.
18. Webb D, Fayad P, Wilbur C, Thomas A, Brass L. Effects of a specialized team on stroke care. The first two years of the Yale stroke program. Stroke 1995; 26:1353-1357.
19. Bowen J, Yaste C. Effect of a stroke protocol on hospital costs of stroke patients. Neurology 1994; 44:1961-1964.
20. Wentworth D, Atkinson R. Implementation of an acute stroke program decreases hospitalization costs and length of stay. Stroke 1996; 27:1040-1043.
21. Gomez C, Malkoff M, Sauer C, Tulyapronchote R, Burch C, Banet G. Code stroke. An attempt to shorten inhospital therapeutic delays. Stroke 1994; 25:1920-1923.
22. Bratina P, Greenberg L, Pasteur W, Grotta J. Current emergency department management of stroke in Houston, Texas. Stroke 1995; 26:409-414.
23. Kothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. Stroke 1995; 26:937-941.
24. Kothari R, Brott T, Broderick J, Hamilton C. Emergency physicians. Accuracy in the diagnosis of stroke. Stroke 1995; 26:2238-2241.
25. Davalos A, Castillo J, Martinez-Vila E, for the Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Delay in neurologic attention and stroke outcome. Stroke 1995; 26:2233-2237.
26. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Factors delaying hospital admission in acute stroke: the Copenhagen Stroke Study. Neurology 1996; 47:383-387.
27. Williams L, Bruno A, Rouch D, Marriott D. Stroke patients' knowledge of stroke. Influence on time to presentation. Stroke 1997; 28:912-915.
28. Spearman MP, Jungreis CA, Wehner JJ, Gerszten PC, Welch WC. Endovascular thrombolysis in deep cerebral venous thrombosis. AJNR Am J Neuroradiol 1997; 18:502-506.
29. Kim S, Suh J. Direct endovascular thrombolytic therapy for durai sinus thrombosis: Infusion of alteplase. AJNR Am J Neuroradiol 1997; 18:639-645.
30. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 1997; 349:1569-1581. A large, multicenter trial of aspirin or high/low dose subcutaneous heparin tor acute ischemic stroke.
31. Bousser M. Aspirin or heparin immediately after a stroke? Lancet 1997; 349:1564-1565.
32. Hirsh J, Levine M. Low molecular weight heparin. Blood 1992; 79:1-17.
33. Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. W Engl J Med 1995; 333:1588-1593.
34. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischemic stroke. Lancet 1997; 349:1641-1649.
35. Diener H, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J for the Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial. Stroke 1996; 27:76-81.
36. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke. (RANTTAS). Stroke 1996; 27:1453-1458.
37. Markabi S, Selfotel (CGS 19755): the preliminary clinical experience. In: Krieglstein J, Oberpilcher-Schwenk H (editors): Pharmacology of cerebral ischemia. Stuttgart: Wissenschaftiche Verlagsgesellschaft mbH; 1994:635-662.
38. Davis SM, Albers GW, Diener HC, Lees KR, Norris J. Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committee. Lancet 1997; 349:32.
39. Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, et al. Treatment of acute cerebral infarction with a choline precursor in a multi-center, double-blind, placebo-controlled study. Stroke 1988; 19:211-216.
40. Clark W, Warach S, Pettigrew L, Gammans RE, Sabounjian LA for the Citicholine Study Group. A randomized dose-response trial of citicholine in acute ischemic stroke patients. Neurology 1997; 49:671-678.
41. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engt J Med 1991; 325:445-453.
42. European Carotid Surgery Trialists' Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European Carotid Surgery Trial. Lancet 1996; 347:1591-1593.
43. Herbert J, Frechel D, Vallee E, Kieffer G, Gouy D, Berger Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11:180-198.
44. CAPRIE Steering Committee. A randomized, blinded trial of Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348:1329-1339.
45. Scandinavtian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
46. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274-1275.
47. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. Stroke 1997; 28:83-87.
48. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
49. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307.
50. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28:946-950.
51. Grouse JR, 3rd, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin. Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995; 75:455-459.
52. Hodis HN, Mack WJ, LaBrec L, Selzer RH, Liv C, Alaupovic P, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124:548-556.
53. Probstfield JL, Margitic SE, Byington RP, Espeland MA, Furberg CD. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995; 76:47C-53C.
54. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of random-ized trials. JAMA 1997; 278:313-321.
55. Grouse JR 3rd, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157:1305-1310.
56. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events Am J Cardiol 1995; 76:24C-33C
57. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13000 strokes in 450000 people in 45 prospective cohorts. Lancer 1995; 346:1647-1653.
58. Gorelick PB, Schneck M, Berglund LF, Feinberg W, Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology 1997; 16:107-115.